Epidemiology of hepatitis A and vaccination policy
Hepatitis A (HA) is an acute infectious disease of the liver caused by the hepatitis A virus (HAV). HA disease incidence rate is closely linked to the social and economical development. The results of seroepidemiologic studies show that the prevalence of anti-HAV antibodies in population ranges from...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2018-02-01
|
| Series: | Биопрепараты: Профилактика, диагностика, лечение |
| Subjects: | |
| Online Access: | https://www.biopreparations.ru/jour/article/view/27 |
| _version_ | 1797244580751474688 |
|---|---|
| author | I. N. Indikova V. A. Shevtsov A. R. Volgin Yu. V. Olefir V. A. Merkulov V. P. Bondarev |
| author_facet | I. N. Indikova V. A. Shevtsov A. R. Volgin Yu. V. Olefir V. A. Merkulov V. P. Bondarev |
| author_sort | I. N. Indikova |
| collection | DOAJ |
| description | Hepatitis A (HA) is an acute infectious disease of the liver caused by the hepatitis A virus (HAV). HA disease incidence rate is closely linked to the social and economical development. The results of seroepidemiologic studies show that the prevalence of anti-HAV antibodies in population ranges from 15 to almost 100% in various countries of the world. The only reliable way to prevent hepatitis A virus (HAV) for today is the specific prophylactic vaccination. Recently developed inactivated vaccines against HAV have been successfully used in many countries. Vaccines authorized in Russia are safe, possess low reactogenicity and high immunogenicity. Practical experience in using vaccines during the outbreaks of HAV has shown that they possess epidemiological efficacy and provide necessary protection of the population in extreme conditions. This is clearly confirmed by single administration of vaccines to patients in epidemic focus of HAV. Constant regular monitoring of the duration of protection induced by one and two doses of the vaccine is required. The article considers WHO’s position on the use of vaccines for the prevention of HA. It describes the prospects of the further use of vaccines to control the spread of HA. |
| first_indexed | 2024-03-08T21:44:14Z |
| format | Article |
| id | doaj.art-92e6fe800d9e4b27b89a99da6b752c8b |
| institution | Directory Open Access Journal |
| issn | 2221-996X 2619-1156 |
| language | Russian |
| last_indexed | 2024-04-24T19:13:16Z |
| publishDate | 2018-02-01 |
| publisher | Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Биопрепараты: Профилактика, диагностика, лечение |
| spelling | doaj.art-92e6fe800d9e4b27b89a99da6b752c8b2024-03-26T09:10:51ZrusMinistry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Биопрепараты: Профилактика, диагностика, лечение2221-996X2619-11562018-02-0104111627Epidemiology of hepatitis A and vaccination policyI. N. Indikova0V. A. Shevtsov1A. R. Volgin2Yu. V. Olefir3V. A. Merkulov4V. P. Bondarev5Federal State Budgetary Institution «Scientific Centre on Expert Evaluation of Medical Application Products» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «Scientific Centre on Expert Evaluation of Medical Application Products» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «Scientific Centre on Expert Evaluation of Medical Application Products» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «Scientific Centre on Expert Evaluation of Medical Application Products» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «Scientific Centre on Expert Evaluation of Medical Application Products» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «Scientific Centre on Expert Evaluation of Medical Application Products» of the Ministry of Health of the Russian FederationHepatitis A (HA) is an acute infectious disease of the liver caused by the hepatitis A virus (HAV). HA disease incidence rate is closely linked to the social and economical development. The results of seroepidemiologic studies show that the prevalence of anti-HAV antibodies in population ranges from 15 to almost 100% in various countries of the world. The only reliable way to prevent hepatitis A virus (HAV) for today is the specific prophylactic vaccination. Recently developed inactivated vaccines against HAV have been successfully used in many countries. Vaccines authorized in Russia are safe, possess low reactogenicity and high immunogenicity. Practical experience in using vaccines during the outbreaks of HAV has shown that they possess epidemiological efficacy and provide necessary protection of the population in extreme conditions. This is clearly confirmed by single administration of vaccines to patients in epidemic focus of HAV. Constant regular monitoring of the duration of protection induced by one and two doses of the vaccine is required. The article considers WHO’s position on the use of vaccines for the prevention of HA. It describes the prospects of the further use of vaccines to control the spread of HA.https://www.biopreparations.ru/jour/article/view/27вирусный гепатит авакцинопрофилактикаинактивированные вакциныиммуногенностьhepatitis a virusvaccinationinactivated vaccinesimmunogenicity |
| spellingShingle | I. N. Indikova V. A. Shevtsov A. R. Volgin Yu. V. Olefir V. A. Merkulov V. P. Bondarev Epidemiology of hepatitis A and vaccination policy Биопрепараты: Профилактика, диагностика, лечение вирусный гепатит а вакцинопрофилактика инактивированные вакцины иммуногенность hepatitis a virus vaccination inactivated vaccines immunogenicity |
| title | Epidemiology of hepatitis A and vaccination policy |
| title_full | Epidemiology of hepatitis A and vaccination policy |
| title_fullStr | Epidemiology of hepatitis A and vaccination policy |
| title_full_unstemmed | Epidemiology of hepatitis A and vaccination policy |
| title_short | Epidemiology of hepatitis A and vaccination policy |
| title_sort | epidemiology of hepatitis a and vaccination policy |
| topic | вирусный гепатит а вакцинопрофилактика инактивированные вакцины иммуногенность hepatitis a virus vaccination inactivated vaccines immunogenicity |
| url | https://www.biopreparations.ru/jour/article/view/27 |
| work_keys_str_mv | AT inindikova epidemiologyofhepatitisaandvaccinationpolicy AT vashevtsov epidemiologyofhepatitisaandvaccinationpolicy AT arvolgin epidemiologyofhepatitisaandvaccinationpolicy AT yuvolefir epidemiologyofhepatitisaandvaccinationpolicy AT vamerkulov epidemiologyofhepatitisaandvaccinationpolicy AT vpbondarev epidemiologyofhepatitisaandvaccinationpolicy |